Welcome to our dedicated page for MYRIAD GENETICS SEC filings (Ticker: MYGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Myriad Genetics Inc. filings document the regulatory record of a molecular diagnostics and precision medicine company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue and test-volume information, guidance, and product-related operating updates tied to Cancer Care Continuum, Prenatal Health, Mental Health, Precise MRD, and MyChoice CDx.
The company's proxy materials cover board matters, executive compensation, equity awards, and annual meeting governance. Other current reports document officer transitions, compensatory arrangements, and amendments to previously furnished earnings materials, providing formal disclosure of governance changes and financial-reporting corrections.
State Street Corporation reported beneficial ownership of common stock of Myriad Genetics, Inc.. State Street disclosed beneficial ownership of 4,985,060 shares of common stock, representing 5.3% of the class.
All voting and dispositive authority is held on a shared basis through asset management subsidiaries, with 4,866,068 shares having shared voting power and 4,985,060 shares having shared dispositive power, and no sole voting or dispositive power reported.
Myriad Genetics, Inc. reported second quarter 2026 revenue of $190.7 million, an 11% decline year-over-year, as total test volumes were essentially flat at 379,000 but average revenue per test fell 9%, including an $11.0 million revenue reduction from updated collection estimates. Gross margin was 66.6%, down 460 basis points from the prior-year quarter, and operating loss was $38.9 million. Net loss was $43.2 million, or $0.46 per share. Adjusted EBITDA was $(16.9) million.
Cancer Care Continuum revenue was $114.1 million with 6% volume growth, Prenatal Health revenue was $39.8 million, down 16%, and Mental Health revenue was $36.8 million, down 3%. The company highlighted launches and expansions including Prolaris + AI and broader Precise MRD usage, and submitted Precise MRD breast for MolDX Medicare coverage. Cash and cash equivalents were $115.2 million with long-term debt of $120.7 million. For full-year 2026, Myriad now guides revenue to $770–$790 million and Adjusted Gross Margin to 66–67%, and has suspended prior Adjusted EBITDA guidance while implementing its Ascend efficiency initiative and broader strategic review.
Myriad Genetics director Daniel Skovronsky filed a Form 4 reporting his direct holdings in the company. The filing lists ownership of 195,507 shares of Common Stock after the reported entry. The record is characterized as a holdings entry, not as a new purchase or sale.
Myriad Genetics, Inc. reported that Board member Daniel M. Skovronsky, M.D., Ph.D., resigned as a director effective June 17, 2026. The company states his resignation was not due to any disagreement with Myriad Genetics or any matter related to its operations, policies, or practices.
MYRIAD GENETICS INC President and CEO Samraat S. Raha acquired 3,542 shares of common stock on June 11, 2026. The shares were obtained at $3.936 per share under the company’s Amended and Restated 2012 Employee Stock Purchase Plan, as a compensation-related award.
After this acquisition, Raha directly holds 1,068,083 shares of Myriad Genetics common stock. This filing reflects a routine, plan-based share purchase rather than an open-market buy or sell decision.
Myriad Genetics Chief Commercial Officer Brian J. Donnelly acquired 5,000 shares of common stock through the company’s Amended and Restated 2012 Employee Stock Purchase Plan. The shares were acquired at a price of $3.936 per share in a transaction exempt under Rule 16b-3(d) and Rule 16b-3(c).
After this acquisition, Donnelly directly holds 573,363 shares of Myriad Genetics common stock, indicating this is a relatively small, routine, compensation-related increase in his overall equity position rather than an open-market purchase.
Myriad Genetics Inc. director Rashmi Kumar sold 15,000 shares of Common Stock in an open-market transaction. The shares were sold on 2026-06-08 at a weighted average price of $4.4562 per share, in multiple trades ranging from $4.37 to $4.63.
After this sale, Kumar directly owns 171,889 shares of Myriad Genetics Common Stock. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
Myriad Genetics director Daniel Skovronsky received an equity award of 59,701 shares of common stock in the form of restricted stock units. The grant was made at no cash cost to him and represents compensation rather than an open-market purchase.
Each restricted stock unit converts into one share of Myriad Genetics common stock and will vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the grant. After this award, Skovronsky holds a total of 195,507 shares of common stock directly.